# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emile Griffith (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX005-SYN
- Date: 2026-05-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Fairbanks-Ochieng, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of memory loss and PTSD, seen the same day by cognitive neurology. **S**

## History of present illness

Emile Griffith returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Lindgren at the memory clinic. He had a brain MRI this morning. His intake blood count, metabolic panel, B12 and TSH were normal. He started sertraline 25 mg each morning after intake; he had mild nausea for three days, which has gone, and no dizziness or bleeding. The nightmares about the title fight still come most nights. His first session of cognitive processing therapy is booked for next week. He missed the physical therapy evaluation booked last week: the card was mislaid and nobody called to remind him. He has had no falls and has not travelled alone since intake. He has had no thoughts of suicide. **S**

| Element | Detail |
|---|---|
| MRI | Mild frontal-predominant atrophy; old right frontal injury; seven microbleeds; cavum septi pellucidi; hippocampi normal for age |
| CDR | Global 0.5, sum of boxes 2.0 |
| Sodium | 138 mmol/L two weeks into sertraline |
| Sertraline | 25 mg; nausea for three days, now gone |
| Safety | No thoughts of suicide; safety plan on the refrigerator |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Forgetfulness and slowness in finding words for names; no headaches, weakness, tremor or change in walking |
| Psychiatric | Positive | Nightmares most nights, guilt about the fight, mood low some days; no hallucinations, suspiciousness or thoughts of suicide |
| Gastrointestinal | Negative | Nausea in the first three days of sertraline, now gone; no diarrhea |
| Musculoskeletal | Negative | No falls |

4 systems reviewed. **S**

## Current medications

- Sertraline 25 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.8 kg; BMI 25.5 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; CDR (global): 0.5. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 138 mmol/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and warm; blood pressure 130/78 mmHg; pulse 68; weight 73.8 kg |
| Neurological | Cranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; slightly wide-based gait with one side-step on tandem walking; no dysarthria |
| Mental status | Alert and courteous; needs cues to recall the plan from intake; tearful briefly when the fight is discussed; no psychotic symptoms; denies thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Memory loss and confusion** (R41.3). Dr. Haddad-Lindgren finds mild cognitive impairment (CDR 0.5) with a frontal-subcortical pattern: slowed thinking, poor set-shifting and retrieval that improves with cues. The MRI shows changes seen after traumatic brain injury (an old right frontal injury, microbleeds and a cavum septi pellucidi) with hippocampi normal for age. Repetitive head impacts over a long career and the severe assault thirteen years ago are the most likely causes; the NINDS criteria for traumatic encephalopathy syndrome, which are research criteria, are probably met; PTSD, depression and poor sleep add to the difficulty; Alzheimer's disease is less likely but not excluded. **S**
   - Neuropsychological testing in three weeks.
   - Results and next steps at the six-week visit, with his care partner present at his request.
2. **Post-traumatic stress disorder, chronic** (F43.12). Sertraline 25 mg tolerated and sodium normal; too early for benefit. No thoughts of suicide. **S**
   - Continue sertraline 25 mg; raise to 50 mg at the six-week visit if tolerated.
   - First cognitive processing therapy session next week.
   - Safety plan and 988 reviewed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake, with delayed recall helped by cues |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Completed today | Global CDR 0.5 (sum of boxes 2.0); independent in personal care; reminders for appointments and help with bills (Functional Activities Questionnaire 6) |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and vision | Once at diagnosis | Up to date | Completed at intake: blood count, metabolic panel, B12 418 pg/mL and TSH 2.1, normal; PHQ-9 9; STOP-Bang 2 (low risk); whispered-voice test and near vision normal; no anticholinergic or sedating medicines |
| Imaging | Structural brain MRI | Once at diagnosis; repeat only with an atypical course or focal change | Completed today | Mild frontal-predominant atrophy; old right frontal encephalomalacia; seven microbleeds; cavum septi pellucidi; hippocampi normal for age; no infarct, mass or subdural collection |
| Survey | Neuropsychological testing | At diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with change | Ordered | Booked in three weeks |
| Laboratory | Alzheimer's disease biomarkers (blood, CSF or amyloid PET) | When the result would change diagnosis or management | Due | To be discussed with the testing results |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline 25 mg only; no anticholinergic, sedating or over-the-counter sleep medicines |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Up to date | PHQ-9 9 at intake, item 9 scored 0; no thoughts of suicide today; next PHQ-9 at six weeks |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Up to date | PCL-5 41 at intake; next at six weeks |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Completed today | Two weeks on 25 mg: nausea resolved; no dizziness, falls or bleeding; sodium 138 mmol/L |
| Referral | Trauma-focused psychotherapy (cognitive processing therapy) | Weekly, about twelve sessions | Referred | With the clinic psychologist; first session next week |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Up to date | Timed Up and Go 13 seconds at intake; one fall on ice last winter; no fall since |
| Referral | Physical therapy for balance and strength | Once, after a Timed Up and Go above 12 seconds | Deferred | Deviation: the evaluation booked for last week was missed because the appointment card was mislaid and no reminder call was made. No fall has occurred, so no harm is known. Corrective action: rebooked at the first opening, in about five weeks, with a reminder call to him and his care partner and the date on the wall calendar |
| Examination | Driving safety | At diagnosis and each follow-up | Not indicated | He does not drive |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | Travels with his care partner; no firearms; medicines kept by his care partner |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 130/78 mmHg; weight 73.8 kg |

## Goal progress

- Find the cause of the memory problems and explain it to him in a way he can take in. In progress; target 2026-06-16. **S**
- A clinically meaningful fall in PTSD symptoms (PCL-5 down at least 10 points) by four months. In progress; target 2026-09-15. **S**
- Nightmares no more than about once a week, with at least six hours of sleep most nights. In progress; target 2026-10-27. **S**
- No falls, with a balance and strength program. In progress; target 2026-10-27. **S**
- Name a health care agent and record his goals of care while he can take part fully. In progress; target 2026-08-04. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863 (Katz DI et al.)
- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026), Aether Forge
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- STEADI (Stopping Elderly Accidents, Deaths and Injuries): Clinical Resources (2024), Centers for Disease Control and Prevention

## Follow-up

- Neuropsychological testing in three weeks. Six-week review with the results, PHQ-9 and PCL-5. Call the clinic or 988 at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2026-06-16: six-week review: neuropsychological testing, the diagnosis and the plan, PTSD treatment, safety and caregiver support. **S**
